Bellerophon Therapeuetics (NASDAQ:BLPH) has announced it and the US Food and Drug Administration (FDA) have agreed on a regulatory approval pathway for INOpulse for patients with hypertension related to interstitial lung disease. As quoted in the press release: In January 2019, the Company reported positive results from Cohort 1 of its ongoing Phase 2b randomized, … Continued
The post Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse appeared first on Investing News Network.